There are currently 28 active clinical trials seeking participants for Colorectal Neoplasms research studies. The states with the highest number of trials for Autism participants are California, Other, Texas and Ohio.
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249
Recruiting
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Massachusetts General Hospital ., Boston, Massachusetts +13 locations
Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
Register for Updates
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
NCT05091346
Recruiting
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab. The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab (melanoma, colorectal cancer [CRC], hepatocellular carcinoma [HCC]) or of E7386 in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: University of California, Los Angeles, Los Angeles, California +35 locations
Conditions: Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
Register for Updates
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
NCT03597581
Recruiting
RGX-202-01 (ompenaclid) is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI +/- bevacizumab. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of orally administered RGX-202-01 with or without FOLFIRI +/- bevacizumab (single agent or combination therapy) will be evaluate... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Arizona Oncology Associates, PC - HAL, Prescott Valley, Arizona +16 locations
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
Register for Updates
Longitudinal Performance of Epi proColon
NCT03218423
Recruiting
This study will evaluate longitudinal performance of Epi proColon with respect to test positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up colonoscopy and diagnostic yield, as well as assay failure rates.
Gender:
All
Ages:
Between 50 years and 74 years
Trial Updated:
10/29/2021
Locations: Veterans Affairs San Diego Healthcare System, San Diego, California +5 locations
Conditions: Colorectal Cancer, Colorectal Neoplasms
Register for Updates